分析人士:兩大因素誤使信達生物(1801.HK)股價波動
格隆匯1月27日丨信達生物(1801.HK)近兩日走出明顯的下跌行情,兩日內最大跌幅超20%,且股價創出2020年4月以來新低,最新市值471億港元。分析人士稱,信達生物最近兩日股價的波動可能主要受兩大因素引發:一是花旗銀行在日前的電話會上透露,美國出於臨牀資源和競爭格局,不想再有更多PD-1,此次應該不會同意信達PD-1獲批。但分析人士認為,相比於信達2020年跟禮來簽署出海合作時57港元左右的股價,憑藉着現在公司在中國的PD-1銷售佔據頭部位置,其他還有5個產品在銷售中,因此目前信達生物32港元的價格實際上已遠遠低於其應有的價值。二是吉利德暫停了其CD47美國MDS三期臨牀試驗。但分析人士指出,與吉利德不同,信達在1b期做了更多的劑量探索和安全性及療效性的探索,給藥方案不一樣,可以看到1b期的安全性和療效性較好。整體上信達生物並不受影響,吉利德的暫停甚至給了後面的CD47趕超的機會。分析人士認為,信達生物目前股價估值中,已經沒有PD-1美國獲批部分,花旗銀行召開的專家會議讓市場情緒陷入短暫性的無謂恐慌,市場反應明顯過度。另外,吉利德暫停其CD47美國MDS三期臨牀試驗的消息實質上對信達幾乎沒有影響,目前公司價格被嚴重低估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.